Pfizer (NYSE:PFE) Trading Up 0.9%

Pfizer Inc. (NYSE:PFE)’s stock price traded up 0.9% on Tuesday . The stock traded as high as $29.56 and last traded at $29.36. 9,133,759 shares changed hands during trading, a decline of 77% from the average session volume of 39,704,047 shares. The stock had previously closed at $29.10.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PFE. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, July 10th. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Barclays upped their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 10th. Finally, Morgan Stanley lifted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $34.50.

Pfizer Trading Up 1.2 %

The stock has a market cap of $166.82 billion, a PE ratio of -489.25, a price-to-earnings-growth ratio of 1.13 and a beta of 0.69. The company has a 50 day moving average of $28.27 and a two-hundred day moving average of $27.71. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.23 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.71%. Pfizer’s payout ratio is currently -2,799.53%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Olistico Wealth LLC purchased a new stake in shares of Pfizer in the second quarter valued at approximately $25,000. Creekmur Asset Management LLC purchased a new position in Pfizer during the fourth quarter worth approximately $32,000. Trivant Custom Portfolio Group LLC boosted its stake in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares during the last quarter. Tennessee Valley Asset Management Partners purchased a new stake in Pfizer in the 4th quarter valued at $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new position in shares of Pfizer during the 4th quarter worth $37,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.